Pantziarka Pan, Verbaanderd Ciska, Huys Isabelle, Bouche Gauthier, Meheus Lydie
Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium; The George Pantziarka TP53 Trust, London KT1 2JP, UK.
Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Semin Cancer Biol. 2021 Jan;68:186-191. doi: 10.1016/j.semcancer.2020.01.008. Epub 2020 Jan 23.
Drug repurposing is a strategy that aims to develop novel cancer treatments through the reuse of existing medicines developed in other disease areas. Such a strategy includes the identification of candidate drugs, clinical development, drug licensing, reimbursement and clinical implementation. This review outlines a literature-based approach to candidate selection with illustrative examples in osteosarcoma, pancreatic cancer and perioperative therapies. Key issues related to the development of clinical trials, drug licensing/approval and clinical adoption are explored to highlight some of the obstacles that must be overcome to successfully repurpose a drug as a new therapeutic option.
药物重新利用是一种旨在通过重新使用在其他疾病领域开发的现有药物来开发新型癌症治疗方法的策略。这种策略包括候选药物的识别、临床开发、药物许可、报销和临床实施。本综述概述了一种基于文献的候选药物选择方法，并以骨肉瘤、胰腺癌和围手术期治疗为例进行说明。探讨了与临床试验开发、药物许可/批准和临床应用相关的关键问题，以突出将一种药物成功重新用作新治疗选择必须克服的一些障碍。
